Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience

Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era

(2019) Roosa E. I. Prusila et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

(2019) Emmanuel Bachy et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis

(2018) Massimo Federico et al.   Lancet Haematology

Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era

(2018) Alfredo Rivas-Delgado et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts

(2018) Clémentine Sarkozy et al.   JOURNAL OF CLINICAL ONCOLOGY

Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials

(2017) Qian Shi et al.   JOURNAL OF CLINICAL ONCOLOGY

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

(2015) Carla Casulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study

(2014) H R Junlén et al.   LEUKEMIA

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

(2013) D. Tan et al.   BLOOD

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

(2008) G. Salles et al.   BLOOD

Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma

(2008) Robert Marcus et al.   JOURNAL OF CLINICAL ONCOLOGY